All are true about patients with trigeminal neuralgia except:

Explanation

## Correct Answer: A. Deep seated pain Trigeminal neuralgia (TN) is characterized by **sharp, stabbing, lancinating pain** — not deep-seated pain. This is the cardinal discriminating feature. The pain is superficial, burning, or electric-shock-like in quality, typically triggered by light touch, chewing, or cold wind on the face. It follows the distribution of one or more divisions of the trigeminal nerve (CN V), most commonly V2 (maxillary) and V3 (mandibular). The pain is paroxysmal, lasting seconds to minutes, with pain-free intervals. Importantly, neurological examination reveals **no objective sensory loss** — this absence of signs despite severe pain is pathognomonic and distinguishes TN from other neuropathies. The condition is more common in females (female:male ratio ~3:2) and typically presents after age 50, though younger presentations occur in multiple sclerosis. In India, TN prevalence is estimated at 4–13 per 100,000, with vascular compression of the trigeminal nerve root being the most common cause. Option A incorrectly describes the pain as "deep-seated," which contradicts the superficial, lancinating nature of TN pain. ## Why the other options are wrong **B. More common in females** — This is TRUE. Trigeminal neuralgia shows a female predominance with a female-to-male ratio of approximately 3:2. This epidemiological fact is well-established in Harrison and is a high-yield point for NEET PG. The question asks for what is FALSE, so this option is correctly excluded from the answer. **C. No objective signs of sensory loss** — This is TRUE and is a hallmark feature of TN. Despite severe pain, neurological examination shows intact sensation, normal reflexes, and no motor weakness. This absence of objective neurological signs despite debilitating pain is a key diagnostic criterion and helps differentiate TN from other trigeminal neuropathies or structural lesions. **D. Pain along V2 and V3 division of trigeminal nerve** — This is TRUE. TN most commonly affects the maxillary (V2) and mandibular (V3) divisions, either alone or together. V1 (ophthalmic) involvement is less frequent. The pain strictly follows dermatomes of the trigeminal nerve, making this a defining characteristic of the condition. ## High-Yield Facts - **Lancinating, electric-shock-like pain** — NOT deep-seated; superficial, paroxysmal quality is pathognomonic. - **Female predominance** (3:2 ratio) with typical onset after age 50; younger patients suggest MS as underlying cause. - **No objective sensory loss** on examination despite severe pain — absence of signs is diagnostic and distinguishes TN from other neuropathies. - **V2 and V3 divisions** most commonly affected; V1 involvement is rare; pain follows strict trigeminal dermatomal distribution. - **Vascular compression** of trigeminal nerve root (neurovascular conflict) is the most common pathophysiological mechanism identified on MRI. - **Carbamazepine** is the first-line drug in India (DOC); oxcarbazepine and pregabalin are alternatives; surgical options include microvascular decompression. ## Mnemonics **TN Pain Character — SHARP** **S**uperficial (not deep) | **H**igh intensity | **A**cute onset | **R**ecurrent paroxysms | **P**ain-free intervals. Helps recall that TN pain is lancinating and superficial, never deep-seated. **TN Diagnosis — NO SIGNS** **N**o objective sensory loss | **O**nly pain (no motor/reflex changes). This mnemonic emphasizes the paradox of severe pain with normal neurological examination — the hallmark of TN. ## NBE Trap NBE pairs "deep-seated pain" with trigeminal neuralgia to trap students who confuse TN with other chronic pain syndromes (e.g., atypical facial pain or temporomandibular disorders). The superficial, lancinating quality of TN is the key discriminator. ## Clinical Pearl In Indian clinical practice, a patient presenting with sudden, shock-like facial pain triggered by chewing or cold wind, with completely normal sensory examination, is trigeminal neuralgia until proven otherwise. Starting carbamazepine 100 mg BD and titrating up is the standard approach; if pain persists despite adequate dosing, imaging (MRI with CISS sequence) to rule out MS or space-occupying lesion is warranted. _Reference: Harrison Ch. 379 (Trigeminal Neuralgia); Robbins Ch. 28 (Peripheral Nerve Disorders)_